Register Login

KALA BIO, INC. (KALA)

SymbolKALA
NameKALA BIO, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address100 BEAVER STREET,SUITE 201, WALTHAM, Massachusetts, 02453, United States
Telephone+1 781 996-5252
Fax—
Email—
Websitehttps://www.kalarx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001479419
Description

Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease.

Additional info from NASDAQ:
Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease.

2026-05-15 17:24

New Form SCHEDULE 13G/A - KALA BIO, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062584 <b>Size:</b> 14 KB

Read more
2026-05-07 20:07

(99% Neutral) KALA BIO, INC. (KALA) Announces Business Combination

Read more
2026-05-07 18:26

New Form S-3 - KALA BIO, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001829126-26-004790 <b>Size:</b> 1 MB

Read more
2026-05-07 13:00

KALA BIO Announces Reverse Stock Split

Read more
2026-04-21 11:00

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Read more
2026-04-15 17:04

New Form 10-K - KALA BIO, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001104659-26-043782 <b>Size:</b> 13 MB

Read more
2026-04-01 10:45

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Read more
2026-03-30 12:45

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Read more
2026-03-17 20:21

📋 ANDREW I KOVEN (Director) plans to sell 14K shares of KALA BIO, INC. (at $0.26 each, total $4K) Filed: Mar 17, 2026 | ID: 002718

Read more
2026-03-17 17:59

New Form D - KALA BIO, Inc. <b>Filed:</b> 2026-03-17 <b>AccNo:</b> 0001829126-26-002408 <b>Size:</b> 8 KB

Read more